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Protein–protein interactions (PPIs) are implicated in the majority of cellular processes by enabling and
regulating the function of individual proteins. Thus, PPIs represent high-value, but challenging targets for
therapeutic intervention. The development of constrained peptides represents an emerging strategy to
generate peptide-based PPI inhibitors, typically mediated by a-helices. The approach can confer
significant benefits including enhanced affinity, stability and cellular penetration and is ingrained in the
premise that pre-organization simultaneously pays the entropic cost of binding, prevents a peptide from
adopting a protease compliant b-strand conformation and shields the hydrophilic amides from the
hydrophobic membrane. This conceptual blueprint for the empirical design of peptide-based PPI
inhibitors is an exciting and potentially lucrative way to effect successful PPI inhibitor drug-discovery.
However, a plethora of more subtle effects may arise from the introduction of a constraint that include
changes to binding dynamics, the mode of recognition and molecular properties. In this review, we
summarise the influence of inserting constraints on biophysical, conformational, structural and cellular
behaviour across a range of constraining chemistries and targets, to highlight the tremendous success
that has been achieved with constrained peptides alongside emerging design opportunities and challenges.ongshuang Wang received his
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View Article Online1 Introduction
Protein–protein interactions (PPIs) mediate virtually all biolog-
ical processes and are associated with many diseases. PPIs have
historically represented challenging targets for competitive
(orthosteric) inhibitor discovery; they typically involve interac-
tion of comparatively large and less featured protein surfaces, in
comparison to established drug targets.1
The a-helix has been shown to have a relatively high preva-
lence in the human PPI interactome2,3 and represents a generic
pharmacophore for ligand design.4 As a result, a-helix mediated
PPIs have attracted signicant attention for the development of
selective probes and drug candidates to meet a plethora of
unmet therapeutic needs.5 At such PPI interfaces, the a-helix of
one protein is bound within a groove on the binding partner. A
signicant number of such interactions involve short peptide
motifs;6 these are typically located within intrinsicallyPeiyu Zhang received his Bach-
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Chem. Sci.disordered regions (IDRs),7–9 thus the a-helix is transiently
stabilized on formation of the PPI. Crystallographic and struc-
tural analyses of these interfaces can facilitate the development
of peptides (or judiciously designed small molecules) that
mimic the helix both topologically and/or topographically; such
mimetics (termed ‘peptidomimetics’) offer a promising starting
point in the development of PPI inhibitors and have led to
clinical candidates.10 Constrained peptides represent a branch
of peptidomimetics that have emerged as powerful tools for
perturbing PPIs; chemically constraining (or ‘stapling’)
a peptide in its bioactive a-helical conformation has been re-
ported to confer numerous benets such as enhanced protease
resistance, stability in cells, increased cellular uptake and
improved biophysical properties in comparison to wild-type
sequences.11–13
Just as the position of a constraint within a sequence has
effects on peptide helicity, the nature of chemical linker canAndrew (Andy) J. Wilson is
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View Article Onlinealso inuence its structure and function. Since the pioneering
work of Grubbs14 and Verdine15 to develop hydrocarbon
stapling, an extensive toolkit has been elaborated to chemically
constrain peptides.16,17 These tools include: disulde bonds,
lactam bridges, hydrogen bond surrogates, alkanediyl tethers,
bridges from thiol–ene coupling, triazole-staples from “click”
chemistry and supramolecular approaches, with a number
developed to allow further functionalization via the constrain-
ing linker.17–25 With such synthetic diversity on offer, it is
reasonable to ask how can one predict which staple type will be
most suitable? Different chemical linkers induce helicity in
a given sequence to different extents and, when constraining
a peptide in its bioactive a-helical conformation, the optimal
exibility is target dependent.26
In this review, we provide an overview of constrained
peptides demonstrating non-classical biophysical or structural
behaviour. We focus predominantly on a-helix mediated PPIs
although note the approach has been broadened to other
classes of PPIs.27,28 We collate recent and unusual observations
that highlight the different inuences staple types can have on
both peptide conformation and target binding. Finally, we
discuss the most recent literature on mechanisms of cell
penetration and studies to ascertain the characteristics of con-
strained peptides that enhance cellular uptake. Ultimately, we
intend that this review will aid the rational design and devel-
opment of highly potent and cell penetrating constrained
peptides as PPI inhibitors.Fig. 1 Schematics depicting different binding mechanisms for
peptide–protein interactions; (a) bind and fold (b) conformational
selection. Where binding is conformational-dependent (b), the intro-
duction of a constraint is anticipated to enhance binding affinity (green
dashed line). Where a bind and fold mechanism occurs (a), the intro-
duction of a constraint may have no effect on, or reduce, binding
affinity (red dashed line).2 Enhancing protein binding affinity
Peptides that adopt an a-helical conformation as a part of their
parent protein are oen disordered in solution. Upon peptide-
protein binding, a-helix formation occurs through a nucle-
ation, followed by propagation mechanism.29 The entropic
‘cost’ associated with helix folding may thus impair target
protein binding. Introduction of a chemical linker to constrain
(or ‘staple’) the peptide in its bioactive a-helical conformation
might be anticipated to overcome this entropic cost and
enhance target protein binding affinity, however this is not
always the case and justies application of a more nuanced
appreciation of ligand–receptor binding theory.2.1 The importance of binding kinetics, thermodynamics
and mechanism
The idea that pre-organization of a peptide into its bound
bioactive conformation will enhance target protein binding
affinity is based on various assumptions. One is that the target
protein only recognises the peptide when it forms a helical
structure. Where binding proceeds by such conformational
selection,30 constraining a peptide can be expected to increase
the equilibrium concentration of the bioactive conformer,
resulting in a more efficient interaction with its target (Fig. 1b).
In contrast, this may not be expected for a peptide–protein
interaction where the unstructured peptide is also recognised
by the target. Where a less structured peptide is recognised and
folds on a binding surface, it is best described as a “bind and© 2021 The Author(s). Published by the Royal Society of Chemistryfold” mechanism.31 In these cases, a constrained and pre-
organised peptide might be expected to have limited “ways to
bind” (Fig. 1a), resulting in a slower rate of binding and
unbinding with little or a negative impact on affinity.32
Similarly, the impact of pre-organization on both the
enthalpy and entropy of binding warrants consideration.33,34
When a peptide folds, enthalpy associated with folding includes
contributions from backbone and side chain hydrogen-
bonding, and other electrostatic contributions, together with
enthalpic contributions from changes in solvation.35 Similarly,
the total entropy of folding includes solvent reorganisation,
changes in rotational–translational freedom and conforma-
tional ordering of the peptide.34 For the example of an unbound
peptide in solution, the unconstrained variant will be more
disordered whilst water molecules will be ordered around
exposed backbone amides in contrast to the constrained
peptide.35 Upon folding, the unconstrained peptide will co-
operatively gain new hydrogen-bonds between backbone


























































































View Article Onlineenthalpically favourable contributions to the same extent, yet
less impact from the entropically favourable release of water can
be anticipated.36 Thus, the opposing entropic and enthalpic
contributions (enthalpy–entropy compensation) oen result in
only marginal increase in stability of a folded form i.e. the net
DG of folding may be comparable to the magnitude of a single
non-covalent interaction (i.e. <5 kJ mol1) and this might be
considered the maximum accessible gain arising from pre-
organization (in the absence of additional interactions being
introduced between constrained peptide and target protein; see
later). Such a framework ultimately represents an over-
simplication; making the assumption that constraining
a peptide changes the energetic state relative to the wild-type
sequence is not valid as the sequences are different. Con-
straining a peptide simply increases the stability/energy of its
unfolded form.
In a study to explore how pre-organization of BH3-family
peptides affects their inhibitory potency of the BH3/BCL2-
family PPIs,37 specically BID and BIM BH3 domains with
MCL-1 and BCL-xL, Miles et al. found that whilst the introduc-
tion of a hydrocarbon constraint increased the population of
the bioactive a-helical conformation of the peptides in solution,
this did not enhance their potency.35 In fact, some of the con-
strained peptides exhibited a signicant loss of potency. Co-
crystal structures of the constrained BH3 peptides bound to
the BCl-2 family proteins showed that the constraint induced no
signicant differences in the orientation of hot-spot side chains
or registry of the peptide, nor did the constraint overtly intro-
duce a steric clash with the target protein. Thus, the unexpected
drop in potency could not be explained by the static structure of
the bound complexes. Surface plasmon resonance (SPR) assays
revealed that the rates of binding and unbinding differed
between wild-type and constrained sequences; in all cases, the
introduction of a hydrocarbon constraint resulted in a signi-
cant decrease in both on and off rates consistent with a bind
and fold mechanism of binding. Van't Hoff analyses of uo-
rescence anisotropy direct binding experiments allowed the
contributions of enthalpy and entropy to the interaction to be
determined; these data revealed that the entropic cost of
binding was indeed reduced for the constrained peptide.
However, the favourable change in entropy was compensated
for by an opposing change in the enthalpic contribution to
binding.35 These observations are consistent with what might
be expected when constraining a peptide that interacts with its
target through a bind and fold mechanism of interaction.
Ochsenbein and co-workers also observed enthalpy–entropy
compensation in studies on the histone H3/ASF1 (anti-silencing
function 1) interaction.38 In this work, variant H3 peptides (res
118–135) bearing i, i + 4 hydrocarbon staples in multiple posi-
tions within the sequence were investigated.39 In addition to
highlighting the above discussed limitations in correlating pre-
organization with binding affinity, biophysical analyses also
revealed that promotion of a-helix formation is dependent on
the position at which the constraint is introduced in the
sequence. This is unsurprising, since different peptide
sequences have different propensities for a-helix formation and
replacing different amino acids in a native sequence withChem. Sci.unnatural amino acids (used to incorporate a constraint) will
inuence this natural propensity to differing extents.
Important insight into the effects of constraining peptides40
has been obtained using stapled peptide ligands for the
Eukaryotic translation initiation factor 4E (eIF4E); a protein that
regulates cap-dependent mRNA translation via interactions
with competing binding partners, 4E-BP1 and eIF4G.41,42 Both
4E-BP1 and eIF4G bind to the same canonical groove of eIF4E
and bind via intrinsically disordered regions (IDRs) which form
a-helical motifs when bound. Using molecular dynamics (MD)
simulations it was shown that hydrocarbon constrained eIF4G
peptides experienced changes in structural dynamics when
bound or unbound to eIF4E. Although stabilization of the
unbound peptide in a helical conformation could be readily
achieved, binding could also be impeded by favouring meta-
stable conformations that had to change on target binding to
allow key side chains to adopt the orientation required for
molecular recognition. These analyses were supported by
experimental and structural studies, highlighting the impor-
tance of stabilizing solution conformations that match the
bound conformation. Rational design subsequently led to
stapled-peptides with enhanced target residence time targeting
an unexploited patch on the surface of eIF4E.43 Similar obser-
vations were made by Gallagher et al.44 Initially, the group
measured the helical propensities of the linear wild-type 4E-BP1
and eIF4G peptides and found that the 4E-BP1 sequence
exhibits greater helicity in solution than the eIF4G. SPR was
used to prole the temperature- and salt-dependence of the
peptide–protein interactions; whilst eIF4G binding was found
to depend on electrostatic contributions and vary in binding
kinetics with temperature, 4E-BP1 was relatively unaffected. The
data indicated that although 4E-BP1 and eIF4G form similar
bound structures, the two peptides adopt distinct binding
mechanisms with the 4E-BP1 peptide exhibiting a greater
complementarity for eIF4E and forming a more stable bound
complex.44 By comparing the effects of hydrocarbon stapling on
the two sequences, Garner and co-workers demonstrated
a correlation of the linear 4E-BP1 and eIF4G binding kinetics
with the corresponding stapled peptide properties. Whilst
stapling the more complementary 4E-BP1 sequence improved
affinity and bioactivity (indicating conformational selection
operates for 4E-BP1), stapling eIF4G produced a nonhelical
macrocyclic peptide with poorer affinity for eIF4E than its linear
counterpart. Therefore, this study again emphasized that the
analysis of binding mechanism and kinetics can play a crucial
role in understanding whether an IDR peptide will benet from
the introduction of a conformational constraint.
Jamieson and co-workers adopted a constrained peptide
approach to target the a-helix mediated PPI of mitotic kinase
Aurora-A with microtubule-associated protein TPX2.45 In this
work, a hydrocarbon stapled TPX2 peptide demonstrated
improved binding affinity for Aurora-A and was even shown to
mimic the function of TPX2 in activating autophosphorylation
of the kinase. However, a closer inspection of the thermody-
namic determinants of binding, as measured by Isothermal
Titration Calorimetry (ITC), revealed a surprising nding;


























































































View Article Onlinepopulation of the bioactive a-helix and enhanced the binding
affinity, the entropy of binding for the constrained peptide was
more unfavourable when compared to the wild-type. In
concordance, the constrained peptide had a more favourable
enthalpy of binding, suggesting it made more favourable
interactions with the Aurora-A protein when bound. This
hypothesis was later conrmed via crystallographic analysis, by
superposing the existing structure of Aurora-A in complex with
native TPX2 (PDB: 1OL5) onto a crystal structure of the bound
stapled TPX2 peptide (PDB: 5LXM; Fig. 2a). Although the
hydrocarbon staple itself makes no contacts with the Aurora-A
surface and the crucial hot-spot residues remain in almost
identical orientations between the two structures (Fig. 2b and
c), the staple extends the length of the helix by an additional
turn and alters the conformation of the bound helix, allowing
two additional charged side chains, Glu36TPX2 and Lys38TPX2, to
contribute to hydrogen-bonding interactions with Aurora-A
(Fig. 2d). Thus the less favourable entropy can be accounted
for by the requirement to form a longer more ordered helix so as
to make the additional enthalpically favourable non-covalent
contacts.
Hetherington et al. prepared and investigated a series of
constrained peptides to target HIF-1a/p300;46 a PPI whichFig. 2 Comparison of unconstrained/constrained Aurora-A bound
TPX2 peptides; (a) view of Aurora-A (blue) bound to stapled TPX2 (red,
hydrocarbon staple: orange, PDB: 5LXM) with native TPX2 (purple,
PDB: 1OL5) overlaid. TPX2 residues known to be crucial for binding to
Aurora-A are shown as sticks to highlight the conserved binding mode
between stapled and native TPX2; (b) Tyr8, Tyr10, Asp11, Trp34 and
Phe35; (c) Phe16 and Phe19; (d) orientations of residues Lys38 and
Glu36 differ, promoting additional electrostatic interactions (dashed
lines) between peptide and Aurora-A.45
© 2021 The Author(s). Published by the Royal Society of Chemistryregulates oxygen levels in cells and is oen hijacked by cancer to
supply growing tumours with oxygen.47–49 Here, the peptides
were constrained through reaction of dibromomaleimide with i
and i + 4 Cys residues.21,50 One of the dibromomaleimide (DBM)
stapled HIF-1a peptides demonstrated a signicant enhance-
ment of binding affinity for p300 in comparison to the uncon-
strained native peptide. However, contrary to expectation, the
enhanced inhibition did not correlate with an increase in a-
helicity as shown by circular dichroism (CD) experiments. In an
attempt to explain the benecial effects of introducing the DBM
staple, the group compared MD simulations of the HIF-1a
variants both in solution and in complex with p300. MD
simulations indicated that both the constrained and uncon-
strained peptides showed greater helical character in the bound
state when compared to the unbound peptides, with a more
dramatic increase observed for the DBM stapled peptide. Thus,
the staple-induced affinity enhancement was proposed to occur
as a result of stabilizing the bound state of the peptide in
complex with p300 46 and was supported by experimental CD
difference experiments. In a similar vein, Grossmann and co-
workers also observed that changes in the behaviour of bound
state as a consequence of introducing a constraint are impor-
tant for interaction of Exoenzyme S (Exo S) derived peptides
with 14–3–3 protein although in this case, increased affinity was
attributed to increased dynamics in the peptide-receptor
complex.51
In studies by Strizhak et al. a library of peptide analogues,
based on a known p53/MDM2 peptide discovered by phage
display,53 were stapled with a photoisomerizable diarylethene
(DAE) moiety between the i, i + 7 residues using azide–alkyne
“click” chemistry.52 Each analogue possessed two photo-
isomers, referred to as “open” or “closed”, depending on
exposure to visible or UV light, respectively (Fig. 3a). Analogues
also differed in linker length (n ¼ 1 or 2) and/or N-methylation
(R ¼ H or Me). By utilizing competition assays based on tryp-
tophan uorescence quenching, an interesting observation was
noted; analogues constrained with “open” DAE photoisomers
were consistently stronger binders to MDM2 than their “closed”
counterparts. Moreover, ITC measurements, performed to gain
insight into the thermodynamic parameters of binding,
revealed that binding of the “closed” forms were mostly
enthalpy-driven, whilst the “open” isomers bound with a greater
entropic contribution. Attempts to crystalize the highest affinity
analogue (R ¼ Me, n ¼ 1) bound to MDM2 were successful for
the “open” form (Fig. 3b). The peptide bound to MDM2 as ex-
pected, forming an a-helix, with the Phe3p53, Trp7p53 and
Leu10p53 hot-spot residues occupying the known lipophilic
pockets on the protein surface (Fig. 3b). The linker was shown to
directly interact with the target protein by edge-to-face p-
stacking interactions between the triazole and thiophene
moieties of the linker and Phe55MDM2. The triazole ring also
forms hydrogen bonds to a local water molecule, which, in turn,
forms a hydrogen bond with Gln59MDM2. Although the “open”
isomer has greater conformational freedom, given the struc-
tural data illustrate additional non-covalent interactions can
form, the rationale for the observed greater entropic contribu-
tion to binding in comparison to the “closed” form is not fullyChem. Sci.
Fig. 3 MDM2 binding peptides with photoswitchable constraints that
exhibit distinct thermodynamic signatures; (a) structures of both
“open” and “closed” DAE stapled photoisomers, (R ¼ H or Me, n ¼ 1 or
2) used by Spring and co-workers to target the p53/MDM2 interaction;
(b) crystal structure of MDM2 (blue) in complex with the highest affinity
“open” analogue (red, PDB: 6Y4Q). Residues known to be crucial for
binding to MDM2 are shown as sticks: Phe3, Trp7, Leu10, with the
linker shown in orange making direct or H2O-mediated contacts


























































































View Article Onlineclear. Nonetheless, this example illustrates the potential for the
linker of a constrained peptide to make a contribution to
molecular recognition which we discuss in greater detail in the
following section.Fig. 4 Co-crystal structures of protein-bound constrained peptides
highlighting the potential for contact between constraint and protein;
(a) crystal structure of the MCL-1 SAHBD/MCL-1 complex (PDB:
3MK8)58 and the hydrocarbon staple (orange) of MCL-1 SAHBD makes
additional hydrophobic contacts at the perimeter of the core inter-
action site; (b) a methyl group of the a,a-disubstituted functionality
occupies a groove defined by Gly262, Phe318 and Phe319 of MCL-1
(green); (c) comparison of the ERa bound structures of the native
sequence (purple, PDB: 2QGT) and the stapled peptide SP1 (red, PDB:
2YJD);60 (d) comparison of the hDM2 bound structures of the native
p53 peptide (purple, PDB: 1YCR)61 and the stapled peptide (red, PDB:
3V3B).622.2 Forming more contacts: direct interactions between
staple and target
In designing constrained peptides for modulation of a-helix
mediated PPIs, the constraint has typically been introduced on
the solvent-exposed surface of the a-helix to avoid introducing
a steric clash with the binding surface and/or interfering with
the interaction of hot-spot residues.54–57 However, in a number
of instances the chemical linker has been shown to interact
protably with the target protein to enhance target binding, or
even to change the nature of the interaction. The ability to
design constrained peptides such that the constraint makes
additional, favourable contacts with the target protein could be
benecial for their development. The following examples focus
largely on co-crystal structures that highlight this behaviour and
point to some of the challenges in intentionally designing such
constraints.Chem. Sci.Walensky and co-workers screened a library of stabilized a-
helix BCL-2 domains (SAHBs), and determined that the MCL-1
BH3 helix is itself an MCL-1 inhibitor.58 Through a combina-
tion of site-directed mutagenesis and staple scanning studies,
the group developed an optimized, hydrocarbon stapled MCL-1
peptide (MCL-1 SAHBD). To structurally dene key interactions,
a crystal structure of the stapled peptide bound to MCL-1 was
obtained (Fig. 4a). This crystallographic analysis revealed that
the hydrocarbon staple itself makes discrete hydrophobic
contacts with the perimeter of the MCL-1 binding site (Fig. 4a).
Moreover, a methyl group of the disubstituted unnatural amino
acid was shown to occupy a hydrophobic cavity dened by
Gly262MCL-1, Phe318MCL-1 and Phe319MCL-1 whilst additional
contacts were also evident for the aliphatic side chain (Fig. 4b).
Therefore, the superior binding affinity of the optimized,
hydrocarbon stapled peptide potentially derives from two
contributions: rstly, enhanced a-helicity as a result of pre-
organization and secondly, from additional hydrophobic
contacts by the staple itself. Keating and co-workers similarly
observed extensive interaction between the staple and MCL-1 in
their optimization of a lead peptide for clinical development.59
Phillips et al. highlighted signicant considerations for the
design of constrained peptide inhibitors through the develop-
ment of stapled peptides for nuclear receptors (NRs).60 An 11-
mer stapled peptide with sequence Ac-H-S5-ILH-S5-LLQDS-NH2
(SP1, where S5 is (S)-2-(4-pentenyl)alanine) was designed to
target the coactivator binding site of the estrogen receptor (ER),
and a staple scan carried out to establish the optimal constraint.© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 5 Comparison of constrained p53/hDM2 structures; (a) the
binding site formed in the crystallographically unique M06 complex is
capped by the ‘hinge’ helix of the hDM2 lid (PDB: 4UMN); (b) the
binding pockets that form when hDM2 interacts with SAH-8 (PDB:
3V3B);62 (c) The ‘hinge’ helix caps the bottom of the pocket; (d) Tyr100



























































































View Article OnlineStructures of these complexes and of the peptides in isolation
were studied. For the most potent stapled peptide (SP1), bound
to the ligand binding domain of ERa, inclusion of the hydro-
carbon staple signicantly increased the helicity of the peptide
as judged by CD spectroscopy and NMR. However, the crystal
structure of the SP1/ERa complex revealed that the hydrophobic
staple itself formed favorable contacts with the hydrophobic
surface dened by Val307ERa, Ile310ERa, and Leu490ERa (Fig. 4c).
Comparison with the coactivator protein–peptide complex
(2QGT) revealed a difference of a quarter turn of the helix,
shiing the binding site residues out of register by one position.
Therefore, the introduction of the hydrocarbon staple not only
conformationally restrained the peptide, but induced a non-
canonical mode of interaction with the potential to lead to
non-specic effects.
Later, Baek et al. reported a crystal structure of a hydro-
carbon stapled p53 peptide (SAH-p53-8)63 in complex with its
binding partner, hDM2.62 The crystal structure revealed that
the staple occupied a hydrophobic region on the rim of the
p53 binding site on hDM2, contributing approximately 10% of
the total surface contact area between peptide and protein,
likely enhancing binding affinity. Stapling of the peptide
imposed perfectly helical angles (58/45) on Leu26p53 in
the structure of the constrained peptide resulting in a more
helical bound-state when compared to the wild-type, uncon-
strained counterpart. Moreover, the resulting conformational
change adjusted the Leu26p53 side chain orientation, leading
to a stronger interaction with hDM2 (Fig. 4d). Similar obser-
vations were made for ATSP-7041 – a clinical candidate
peptide-based inhibitor of hDM2 and hDMX developed by
Aileron.64
Ghadessy and co-workers reported a crystal structure of the
hydrocarbon stapled peptide M06 – a variant of one previously
reported by Brown et al.66 – in complex with hDM2.65 The staple
was shown to pack favourably against hydrophobic residues of
hDM2. In addition, theM06/hDM2 crystal structure showed that
the peptide binding groove was capped by the helical ‘hinge’
region of hDM2 (Fig. 5a), near to the C-terminus of the bound
peptide. Comparison with the SAH-p53-8/hDM2 crystal struc-
ture reported by Baek et al., reveals signicant differences
(Fig. 5b).62 In the M06 complex the shorter helix of M06 does not
ll the hDM2 pocket as completely as SAH-p53-8, such that the
hinge region of hDM2 adopts a helical conformation that caps
the pocket, accommodating a tight t of M06 (Fig. 5c). In the
SAH-p53-8/hDM2 structure, Tyr100 of hDM2 points into
a ‘pocket’, stabilized by a hydrogen bond interaction with
Asn29p53. This results in occlusion of the pocket, and in turn,
shields Leu26p53 from solvent (Fig. 5d). It is clear that this
movement of the hinge can be accommodated by Tyr100hDM2
either projecting into (‘closed’ conformation) or out (‘open’
conformation) of the p53 binding site on hDM2. Thus even
though a constraint can form interactions with the target
protein, this example highlights that in doing so, it can induce
conformational changes adding to the challenge of designing
constraints so as to optimize non-covalent interactions with
target proteins.© 2021 The Author(s). Published by the Royal Society of Chemistry2.3 The staple structure: inuence on peptide conformation
and target binding
As discussed in the preceding section, the chemical staple used
to constrain peptides can, in certain cases, interact directly with
the target protein to enhance binding affinity. Minor alterations
to the constraint, such as stereochemistry at the a-position, a-
substituent groups and additional branching on the hydro-
carbon e.g. a g-Me group, insert-site and linker length can thus
signicantly impact on the behaviour of constrained peptides.
Indeed, during the development of the hydrocarbon staple it
was noted that small changes in linker length resulted in
signicant effects on the efficiency of stapling reactions and
consequently the effects on peptide structure.15 Below we
discuss several examples that showcase the diverse inuence of
staple structure on peptide conformation and binding.
Traditionally, incorporation of unnatural a-methyl, a-alkenyl
disubstituted amino acids at i, i + 4, or i, i + 7 positions, is used
to introduce hydrocarbon staples. The a-methyl group was
introduced to the unnatural amino acids for its added helix-
stabilizing effect.15,67 Yeo et al. explored this using the BCL-2/
BH3 family PPIs as a model; comparison of a BID sequence
constrained using a-methyl, a-alkenyl amino acids (BID-DM)
with the a-alkenyl monosubstituted variant (BID-MM) revealed
comparable helicity, resistance to proteolysis and potency for
both.68 However, such behaviour may not hold in every case (cf.
the role of the methyl group in recognizing MCL-1, Section 2.2
and Fig. 4b).Chem. Sci.
Fig. 6 Effects of branching on staple behavior; (a) crystal structure of
hydrocarbon cross-linked macrocyclic peptide (red, hydrocarbon
staple: orange, PDB: 4N7Y) in complex with 14–3–3 (blue): compu-
tational analysis of the 14–3–3 surface reveals cavities 1 and 2 (green)
in proximity to amino acids X(Me)R3 and X(Me)S6 that may be suitable
sites through which to optimize affinity; (b) crystal structures of ESp
(purple) and bRS8 (PDB: 4N7G, red) bound to 14–3–3 (PDB: 4N7Y); (c)
crystal structures of ESp (purple, PDB: 4N7G) and bSS12 (red) in bound
to 14–3–3 (PDB: 4N84);28 (d) structure of branched stapling amino
acids S5, lS and lR; (e) SRC2-SP1 (salmon, PDB: 5DXB), SRC2-SP2
(orange, PDB: 5HYR), and SRC2-SP3 (purple, PDB: 5DX3) adopt



























































































View Article OnlineGrossman and co-workers recently highlighted the profound
effects that a-methylation can have on binding behaviour of
constrained peptides that target the trimeric nuclear tran-
scription factor Y (NF-Y) complex.69 Initially, incorporation of an
i, i + 4 a-methyl, a-alkenyl hydrocarbon staple was shown to
reduce the binding affinity of a native, 19-residue NF-YA peptide
for the NF-YB/C dimer, despite increasing the helicity of the free
peptide in solution from 13% to 47%.70 In contrast a shorter 16-
residue analogue bearing the exact same constraint had
signicantly higher affinity. Since the precise implications of a-
methylation remain unclear, the group expanded their study to
explore whether the a-methyl groups caused the loss of affinity
upon peptide elongation. Switching the N-terminal disubsti-
tuted amino acid for its monosubstituted counterpart68 resulted
in >10-fold affinity enhancement. Both NMR and CD analysis
revealed that the removal of this methyl group had negligible
impact on peptide structure in solution, whilst crystallographic
data revealed that the methyl group did not make direct
contacts with the target protein. The intriguing result was found
to derive exclusively from the conformational characteristics of
the bound peptides; a combination of 2D 1H–1H TOCSY and
transfer-NOE NMR experiments of the constrained peptides in
the presence and absence of NF-YB/C dimer revealed that the a-
methyl group caused the N-terminus of the peptide to deviate
considerably from its bound form.70 The thermodynamic
parameters for binding reect the structural differences; the
fully a-methylated variant exhibited a reduced entropic cost of
binding which was countered by a decrease in binding enthalpy,
whereas the stronger binding mono-methylated variant had
a much more unfavourable entropy of binding that was
compensated by a large enhancement in binding enthalpy.
Such results underscore the importance of biophysical and
structural considerations in the development of potent pepti-
domimetic PPI inhibitors.
The Grossmann group also investigated the effects of
altering the smaller alkyl substituent on the a-carbon of
disubstituted amino acids.71 The group previously reported
a hydrocarbon cross-linked macrocyclic peptide, derived from
the pathogenic protein ExoS, to target the protein interaction
site of the human adaptor protein 14–3–3.28 Originally, this
peptide comprised 11 key amino acids72,73 and contained an R-
and an S-congured a-methyl, a-alkenyl amino acid at positions
3 and 6, X(Me)R3 and X(Me)S6, which were connected to form an
eight membered hydrocarbon linker (Fig. 6a) and found to
adopt an irregular structure when bound to human adaptor
protein 14–3–3.28 This work highlighted the potential to exploit
stapling to stabilize recognition motifs other than the a-helix.
Aer truncation studies identied a minimal sequence which
maintained binding efficiency, the group systematically
replaced the a-methyl group of the disubstituted amino acids,
X(Me)R3 and X(Me)S6, with either hydrogen or a more hydro-
phobic ethyl substituent. These alterations were applied to both
disubstituted amino acids giving a total of seven variants.
Interestingly, all variants with at least one hydrogen-substituent
experienced a loss in binding affinity, whilst those with a-ethyl
substituents were stronger binders. Whilst ethyl-modication at
position 3 resulted in pronounced affinity enhancement, theChem. Sci.same modication at position 6 had little impact; thus, the
effects of introducing ethyl groups at both positions were not
additive. An extensive investigation of the conformational
diversity of the free peptides in solution was used to rationalize
the results. MD simulations identied two predominant
conformer populations of the macrocyclic peptide in solution
and, crucially, the alkyl substituent was observed to play a role
in biasing the conformation towards the higher affinity of the
two dominant conformers. A degree of correlation with log D
values also indicated a role of hydrophobicity consistent with
the larger alkyl substituents making direct contact with the
protein. A co-crystal structure of the optimized macrocyclic
peptide in complex with 14–3–3 revealed that the a-ethyl
substituent in position 3 was able to insert into a hydrophobic
cavity on the protein surface (cavity 1) more so than the smaller
a-methyl group (Fig. 6a). Thus, the minor structural alteration
from a-methyl to a-ethyl had a synergistic stabilizing inuence
on both the free and bound peptide.71 Constrained peptides
with different conguration and length of linkers (i, i + 3 and
bRS8, bSS12) were also developed with increased affinity for 14–© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 7 Crystal structure of bis(triazolyl) staple peptide bound to MDM2
(PDB ID: 5AFG), showing the a-helical conformation and the anti-


























































































View Article Online3–3 in comparison to the wild-type ESp sequence. Protein X-ray
crystallography was employed to explain in mechanistic detail
how the constraint contributed to target binding, and explain
the structure–activity relationship of different linker lengths
and congurations (Fig. 6b and c).28 The backbone in bRS8 was
observed to differ signicantly to that of wild-type ESp, resulting
in loss of direct, as well as water-mediated, polar interactions
and a dislocation of the crucial Leu423 residue. In contrast, the
arrangement of the backbone in bound bSS12 was similar to that
of the wild-type ESp peptide, including water mediated
interactions.
To mimic interactions of branched hydrophobic side chains
of leucine and isoleucine, Speltz et al. created unnatural amino
acids that incorporate a methyl group in the g-position (lS, lR)
of the stapling amino acid S5 (Fig. 6d and e) and introduced
them into a sequence derived from the ERa binding steroid
receptor coactivator 2 (SR2).74 CD analyses of the peptides
indicated that the wild-type sequence is disordered in solution,
while the stapled peptide with an S-g-methyl stapled amino acid
adopted an a-helical conformation and exhibited signicantly
higher affinity for ERa. Moreover, the study found that the
addition of g-methyl groups may positively impact affinity while
having a slightly negative effect on helicity, implying that
constructive interactions with the surface of the receptor are
potentially more important for affinity than conformational pre-
organization. Further crystal structures of bound peptides
containing g-methyl groups in the R or S conguration at the i
or i + 4 (Fig. 6e, SRC-SP1, SRC2-SP2 and SRC2-SP3) positions
demonstrated that such modications are not only tolerated,
but allow the hydrocarbon staple to effectively mimic branched
amino acid side chains.Fig. 8 Constrained peptides as inhibitors of MyoA/MTIP interaction;
(a) comparison of the helices formed by different peptides in complex
with MTIP (blue): the native myoA tail (side chains in aquamarine, PDB:
4AOM), the hydrocarbon stapled peptides (side chains in orange, PDB:
4MZK) and HBS myo A in salmon (PDB: 4MZL); (b) the HBS motif is
positioned at the N-terminus of the myoA peptide and the placement
of the hydrocarbon staple in the center of the helix.762.4 Effects of type of constraint
Spring and co-workers illustrated that the ability of the
constraint to make productive interactions with target proteins
is not limited to hydrocarbon staples. MDM2 binding peptides
based on the phage-derived PMI/PDI peptides were obtained
using a strain-promoted alkyne–azide cycloaddition (SPAAC)
stapling procedure developed to accelerate discovery of cell-
active stapled peptides.75 This in situ stapling/screening
process was used to identify a stapled peptide boasting
improved proteolytic stability and nanomolar binding to its
target protein, MDM2. The a-helical conformation and the anti-
regioconnectivity within the staple were later conrmed by
a crystal structure of the bound-peptide complex. The structure
illustrated that the bis(triazolyl) constrained peptide oriented
the binding triad (Phe3p53, Trp7p53, Leu10p53) correctly to
engage the p53 binding site on MDM2 (Fig. 7) and formed
interactions with the protein.
A further approach used to constrain peptides in an a-helical
conformation is the hydrogen bond surrogate (HBS),18 which
provides a method to avoid unproductive interactions with
protein surfaces. Douse et al. sought to address these challenges
by comparing hydrocarbon stapling and HBS techniques for
peptides targeting the interaction of Plasmodium falciparum
myosin A (myoA) with myoA tail interacting protein (MTIP).76© 2021 The Author(s). Published by the Royal Society of ChemistryInterestingly, the HBS myoA peptide showed comparable
potency to that of wild-type myoA, as may have been expected
given that the HBS constraint was intentionally positioned
across a part of the myoA tail outside the congested MTIP
binding site (Fig. 8a). However, upon introduction of a hydro-
carbon staple, a decrease in potency was observed. Comparison
of the crystal structures obtained for the constrained peptides to
that of the wild-type revealed several key features; rstly, the
fold of MTIP was maintained with the two domains clamped
around the constrained myoA peptides and the hydrocarbon
staple followed the same trajectory as the hydrophobic residues
that were replaced (Fig. 8a). Since the HBS constraint was
positioned at the N-terminus of the helix, steric clashes of the
tether with the congested MTIP binding groove are avoided. In
contrast, the placement of the hydrocarbon staple in the center
of the helix requires the aliphatic chain to plug into the small
hydrophobic core of the MTIP C-terminal domain, preventing
optimal interaction between target protein and constrained


























































































View Article Online3 Determinants of cellular uptake of
constrained peptides
Enhanced cellular uptake is a potential advantage of using con-
strained peptides as modulators of intracellular PPIs.13 Walensky
and co-workers’ 2004 report that a hydrocarbon stapled a-helix
BID BH3 peptide exhibited good cell permeability and in vivo
inhibitory activity against human leukemia xenogras in mouse
models,54 triggered extensive studies on the application of
stapling to other intracellular targets including BCL-2 family
interactions,55,58 and p53/hDM2.77 Although various stapled
peptides have demonstrated promising activity against intracel-
lular PPIs, attributing such activity solely to an on-target mech-
anism and correlating it with enhanced cell permeability is key.
Czabotar and co-workers reported that a hydrocarbon stapled
BIM-BH3-derived peptide, referred to as BimSAHB, exhibited
weaker binding affinity to the BCL-2, BCL-xL, BCL-w and MCL-1
proteins in comparison to the unconstrained counterpart. In
addition, cellular studies showed no evidence of BimSAHB-
induced apoptosis in mouse embryonic broblasts (MEFs) or
Jurkat cells, whilst a positive result was observed in cell lysates.
Taken together, this suggests that the loss of activity of the
stapled peptides in the cell models may result from both the
reduction of binding affinity and poor cell permeability.78
Notably, BimSAHB has a different sequence from that of the
stapled peptide (BIM SAHBA1) reported by Walensky and co-
workers, which did show signicant cytotoxicity and activity on
caspase 3/7 activation in living cells (Table 1).79 BIM SAHBA1 was
shown to enter cells via an endosomal mechanism rather than
a membrane disruption mechanism, whereby the stapled
peptide mainly localized to the mitochondria and multivesicular
bodies of intact cells as demonstrated using electron microscopy
and immunoelectron microscopy.79 In addition to the observa-
tions made by Czabotar and co-workers, the Walensky group
noted the negative net charge of this alternative sequence –
BimSAHB (BIM SAHBA2) – which may contribute to poor cell
permeability; this would be consistent with a previous study
conducted by the group, whereby the replacement of a single Arg
residue with Asp had a marked negative impact on the cellular
uptake of a 21-residue peptide.80,81 These results underscore the
fact that minor sequence variants can confer distinct cell
permeability proles. Moreover, whilst much is known about
entry mechanisms for specic stapled peptides not all questions
are answered.82 Indeed, several studies have indicatedTable 1 Comparative peptide sequences, biophysical properties, cellula
Peptide Sequencea a-Helicity (%
BIM SAHBA1 71
BIM SAHBA2 (BimSAHB) 50
a Residues with negative charges are highlighted in blue; residues with po
the formation of hydrocarbon staples. b Results on OCI-AML3 cells are s
immunoelectron microscopy; an endosomal mechanism of cell entry was
Chem. Sci.constrained peptides have the capacity to induce cell lysis via cell
membrane disruption, which is undesirable and likely to confer
non-specic toxicity.83–85
The major cellular internalization mechanism for con-
strained peptides is proposed to be via ATP-dependent endo-
cytosis.86 Cell-penetrating peptides (CPPs) have been widely
used in cellular studies because of their intrinsic cell perme-
ability.87 The Verdine group compared the internalization
mechanism of three wild-type CPPs and their hydrocarbon
stapled counterparts.86 Contrary to the generally accepted ATP-
dependent mechanism, they found that cell uptake of the
stapled CPPs involved several mechanisms, among which ATP-
independent endocytosis dominated. Nevertheless, the process
by which constrained peptides escape the endosome into the
cytosol remains less well studied.82 Other ATP-independent
internalization mechanisms, such as pore-formation88–90 and
cell membrane disruption,91 have also been observed in studies
of CPPs (Fig. 9). As alluded to above, these mechanisms of
cellular entry are also feasible for stapled peptides, for instance
the Fairlie group reported that replacement of a lactam bridge
with a hydrocarbon staple resulted in cell lysis.85 Li et al. devised
a recombinase enhanced bimolecular luciferase complemen-
tation platform, termed ReBiL, to detect weak PPIs in living
cells, which has proven powerful in studying the behaviour of
stapled peptides.92 Three hydrocarbon stapled peptides,
SAHp53-8,63,77 sMTide-02 66 and ATSP-7041 64 that show higher
binding affinity to the hDM2 or hDMX in vitro than a knownr effects and cellular permeabilities of BIM SAHBA1 and BIM SAHBA2
) Charge
Cellular effectsb
Cell permeabilitycViability (mM) Caspase 3/7 activation
+1 5.5 + +
2 >32 NDd NDd
sitive charges are highlighted in red; X denotes residues participating in
hown here. c Cell permeability was veried by electron microscopy and
conrmed. d Not determined.
Fig. 9 Possible internalization mechanisms of constrained peptides.


























































































View Article Onlinesmall molecule inhibitor, Nutlin-3a, were tested using this
assay; each of the hydrocarbon stapled peptides showed little to
no inhibitory activity in living cells. Under serum-free condi-
tions the activities of the hydrocarbon stapled peptides in cells
increased and cell membrane disruption was observed, whilst
serum had no effect on the interactions in cell lysates, sug-
gesting that the presence of serum inhibits the cellular entry of
the peptides by preventing cell–membrane disruption.
Recently, further modication of constrained peptides has
proven to offer an efficient approach to enhance cell perme-
ability, e.g. by inserting cell-permeable motifs93,94 or self-
assembly-promoting segments.95 However, incorporation of
additional functionality may increase unwanted steric interac-
tions or molecular recognition behaviour, increase synthetic
complexity and may introduce further physicochemical liabili-
ties into the peptide-based inhibitors. Therefore, constrained
peptides lacking further modication represent more favour-
able candidates but their design – like peptide therapeutics in
general – has largely been empirical.96 To rationally design cell-
permeable stapled peptides, it is necessary to understand key
principles for cell permeability.
Lin and co-workers reported that the cellular uptake of
a designed MCL-1 BH3-derived constrained peptide was strongly
correlated to the HPLC retention time.97 The relatively hydro-
phobic peptides showed enhanced cell permeability. Thereaer,
the same group revealed that N-methylation of Ala in stapled
peptides further improved cell permeability, suggesting that
shielding polar groups can promote cellular uptake,98 noting that
N-methylation is considered important for the cell permeability
of numerous natural product and cyclic peptides.82,96,99
Fairlie and co-workers reported that point variants with
hydrophobic amino acid residues exhibited improved activity in
cell assays.100 A series of short lactam-bridged BAD BH3 domain
sequence peptides with one or more incorporated hydrophobic
residues were synthesized. Compared with the wild-type BAD
peptide, the cyclic peptide (Ac-1Nal-Aib-Lys-Nle-Ala-Asp-Asp-
Phe(Cl2)-NH2), incorporated norleucine (Nle), hydrophobic 1-
naphthylalanine (1Nal), aminoisobutyric acid (Aib) and 3,4-
dichlorophenylalanine (Phe(Cl2), (residues in italics denoting
the site of the lactam bridge), showed 2-fold higher activity in
a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay, but exhibited 134-fold weaker binding affinity in
vitro (Table 2) in comparison with the full-length native
sequence. This implied that the enhanced cellular activity of the
short peptide with hydrophobic residues was due to improved
cellular uptake. Li and co-workers also demonstrated that




a Italic residues denote the positions participating in the formation of lac
© 2021 The Author(s). Published by the Royal Society of Chemistryhydrophobic moments (HMs) exhibited stronger binding
affinities with the cell membrane to promote endocytosis,
highlighting the importance of tuning amphiphilicity.101
In addition to sequence hydrophobicity, the hydrophobicity
of the linker itself can have a signicant effect on cellular
uptake. The Li group investigated differences in cell perme-
ability between peptides with different types of constraint,
including the hydrocarbon staple, lactam bridge, triazole, vinyl
sulde, m-xylene and peruoroaryl linkers, based on a peptide
sequence targeting the estrogen receptor (ER) coactivator
binding site.102 In this study, stapled peptides with more
hydrophobic linkers, e.g. hydrocarbon and peruoroaryl
bridges, showed 2-10-fold higher cell permeability than linear
or hydrophilic-linker derivatives in different cell lines (Table 3).
The cell permeability of the stapled peptides with different
staples was found to correlate strongly with the hydrophobicity
using ow cytometry analysis and reverse-phase liquid
chromatography.
There have also been analyses linking the impact of peptide
a-helicity on its cell uptake. The Verdine group systematically
investigated the inuence of the absolute conguration of
building blocks for hydrocarbon stapling on a-helicity and
cellular uptake, based on a model sequence from RNase A.103
The replacement of an (S,S)-congured pair of unnatural amino
acids to an (R,R)-congured pair resulted in loss of a-helicity
and a decrease in cellular uptake. Recently, Li and co-workers
incorporated different substituents, including hydrogen,
methyl, ethyl, isopropyl, phenyl and benzyl groups, into
a peptide targeting estrogen receptor a (ER-a) which was stapled
using thiol–ene chemistry to create an in-tether chiral center.104
These stapled peptides showed different a-helicities although
they were stapled in identical sequence positions. Additionally,
the cell permeability of stapled variants was found to strongly
correlate with their a-helicities, except for the non-substituted
stapled peptide, which showed the highest a-helicity but the
lowest cellular uptake. A related study from Li and co-workers
unambiguously established the relevance of helical content on
cell uptake by comparing uptake of different in-tether
epimers.105 A 2017 study by Ulrich and co-workers also indi-
cated a-helicity was benecial for cell uptake. A series of lactam
stapled CPPs were shown to cause less membrane leakage/lysis
than the unstapled analogues. Importantly here a-helix content
of the peptides when bound to lipid membranes, rather than in
solution, correlated with cell uptake.106 An important study
published by Futaki and co-workers however highlighted
hydrophobicity as more important than helicity.107 A compara-









Fig. 10 Helical wheel diagrams illustrating subtle staple placement; (a)
at the boundary between hydrophobic and hydrophilic surfaces which
is likely to result in improved uptake due to expansion of hydrophobic
surface area; (b) to form a contiguous hydrophobic surface which is
likely to confer superior uptake. Hydrophobic residues and staples are
shown in orange, and hydrophilic and positively charged residues are
Table 3 Comparative a-helicity, hydrophobicity and cell permeability orders of the model peptide targeting the ER coactivatora
Helicity order Hydrophobicity order Cell permeability orderb
Hydrocarbon 1 1 4
Lactam 1 6 6
Triazole 3 5 5
Vinyl sulde 4 4 3
m-Xylene 5 3 2
Peruoroaryl 7 2 1
None (linear) 6 6 7
a The same numbers denote the two stapled peptide showed similar specic properties. b The cell-permeabilities were detected using FAM-labelled


























































































View Article Onlinep53/DM2 interaction) and their unstapled parent were reported
to enter cells via endocytosis. The unstapled peptides with
greater hydrophobicity were shown to have greater cell uptake.
Non-helical cell-permeable stapled peptides have also been re-
ported.108 Spring and co-workers reported a series of double-
triazole stapled peptides based on a nuclear localization
signal (NLS) sequence targeting the interaction between HNF1b
and importin a1, some of which penetrated the cell
membrane.108
Net charge has also been shown to play an important role in
dening the cellular uptake properties of stapled peptides (see
above). In Verdine's study, increasing net charge from 1 to +5
was found to improve the cellular uptake of both hydrocarbon
stapled and stitched peptides86 (a unique form of double
stapled peptides with two contiguous staples bridging three
residues109). However, the constrained peptides with net posi-
tive charge over +7 showed a signicant decrease in cell
permeability.
The cellular uptake of constrained peptides therefore clearly
depends on several driving factors, e.g. hydrophobicity, a-hel-
icity, net charge and the presence of serum. However, cellular
studies have usually focused on one of the key factors inde-
pendently. To provide comprehensive guidelines for design of
cell-permeable constrained peptides, Walensky and co-workers
developed a high-throughput uorescence microscopy
approach tomeasure the cellular uptake of hydrocarbon stapled
peptides with N-terminal FITC labels.84 In this work, the group
systematically tested three classes of hydrocarbon stapled
peptides, including hydrocarbon stapled BIM BH3 helices with
different stapling positions, or diverse single-residue variants,
and hydrocarbon stapled peptides based on another sequence
(RAS binding SOS1). Unbiased quantitative analytical protocols,
used to clarify key biophysical factors inuencing the cellular
uptake of these peptides, revealed that overall hydrophobicity,
net charge, a-helicity, and staple placement are key determi-
nants of cell penetration. The overall hydrophobicity of the
stapled peptides, which was determined by HPLC retention
time, correlates with cellular uptake. The stapled peptides with
high, but not overwhelming hydrophobicity, showed optimalChem. Sci.cell permeability. The position of a staple also plays an impor-
tant role in modulation of cellular uptake of the stapled
peptides. Subtle changes in position of a hydrocarbon staple
between a hydrophobic surface and a hydrophilic surface were
found to improve the cellular uptake of the stapled peptides due
to the expansion of the hydrophobic surface (Fig. 10).84
Furthermore, a-helicity and isoelectric point (pI) were identied
as inuences on cell permeability in Walensky's study.84 In
combination with high a-helicity (61–86%), the relatively
hydrophobic stapled peptides showed excellent cell perme-
ability. However, excessive hydrophobicity coupled with highly
acidic pI was shown to confer a high tendency to induce cell
lysis.
Recently, the Fairlie group tested the cell permeability of
a series of FITC-labelled stapled peptides quantitively via ow
cytometry in living cells without serum.85 A cell-penetrating
peptide, TAT, was selected as a control for 100% of cell entry.
The cell permeability was found to be correlated to the con-
nected hydrophobic surface area (cHSA) and the hydrophobic
moment (mH), which were determined computationally. The
constrained peptides lacking amphipathic structures were not
cell-permeable. In addition, amphipathic peptides lacking
positively charged residues showed poor cell permeability,shown in blue.


























































































View Article Onlinedemonstrating that amphipathicity itself is not sufficient to
promote cellular uptake. Notably, however, the presence of both
a hydrophobic patch (consisting of a hydrophobic bridge and
hydrophobic residues) and a contiguous charged surface
signicantly enhanced the cell permeability of short lactam-
and hydrocarbon-bridged peptides (Fig. 10).85 In this study, the
group also found that the insertion of a hydrocarbon staple is
markedly more likely to induce cell lysis than its lactam-bridged
counterpart.
Finally, peptides that consist of all-D-amino acids generally
have high proteolytic stability but poor cell permeability.110
Recently however, Kannan et al. developed a series of hydro-
carbon stapled and stitched, all-D-amino acid peptides to target
the p53/MDM2 PPI, some of which exhibited improved cell
permeability.111 The group utilised a lactate dehydrogenase
(LDH) release assay to assess the membrane integrity and
a counterscreen assay to validate intracellular p53 engagement.
While themost potent stapled peptides in this study, dPMI-d (5–
12), and stitched peptide, dPMI-d (1–5–12), led to p53 activation
and exhibited no membrane disruption, some of the stapled
peptides caused cellular leakage. It is likely that the increased
cell permeability of the stitched peptide results from the
increased hydrophobicity and conformational rigidity.
However, a double-stapled peptide, dPMI-d (1–5, 9–12), exhibi-
ted stronger binding to MDM2 in an FP assay but poorer cellular
activity in comparison to the stitched peptide, suggesting
a possible loss of cell permeability despite increased hydro-
phobicity and structural stability. Thus, these somewhat
contradictory results for two peptides with increased hydro-
phobicity point to more subtle effects of hydrophobicity on cell
permeability.
Overall, these examples indicate a positive effect on the cell
uptake behaviour arising from introduction of a constraint,
emphasize the complex sequence/cell permeability space that
must be navigated to identify peptides with optimal perme-
ability and provide empirical guidelines to do so. Overall
hydrophobicity, net positive charge, a-helicity, and contiguous
charged and hydrophobic surfaces should be considered as
appropriate starting points. In addition, the cell type is
undoubtedly important and systematic studies will aid in
rening these guidelines; for instance recent studies have
shown better uptake observed for conformationally stabilized
peptides in cancer cells with upregulatedmacropinocytosis.112 It
is noteworthy that a signicant number of these studies make
use of uorescently labelled peptides which may behave
differently to the parent sequence as a consequence of the
uorescent reporter. Making use of novel higher-throughput
assays e.g. the recently reported chloroalkane penetration
assay,113 methods that can rapidly generate diverse and/or
libraries of constrained peptides114,115 and machine learning116
holds signicant potential in this respect. Already, using
combinatorial approaches to constraining peptides targeting
p53/DM2, signicant differences in bioactivity have been
observed with endosomal/lysosomal entrapment playing an
important role and nonspecic toxicity arising from a combi-
nation of staple linker and peptide sequence, not necessarily
either in isolation.117 Similarly, the wealth of systematic and© 2021 The Author(s). Published by the Royal Society of Chemistryphysicochemical studies on cell-penetrating peptides and
(natural product) cyclic peptides118–121 offer much insight that
can be applied to designed constrained peptides targeting PPIs
in future.
4 Conclusions
In the past two decades, development of synthetic constraining
methods has prompted the rapid discovery of peptides to perturb
traditionally “undruggable” PPIs. Compared to wild-type
peptides, constrained peptides are generally expected to have
improved binding affinities, similar binding behaviour and
enhanced cellular uptake. Although not discussed in detail here,
we note also that improved proteolytic stability is an advantage of
constrained peptides, and the reader is directed to numerous
reports that describe this well studied property.13,54 Recent nd-
ings highlight hidden complexities which we have summarized
here to illustrate how the blueprint for rational design of con-
strained peptides is evolving. Binding mechanism and thermo-
dynamics should be considered alongside the nature of any direct
interaction between protein and constraint, subtle structural
inuences on bound/unbound conformation and the complex
sequence-structure space determining cell uptake. Other features
of constrained peptides, e.g. distribution, metabolism, clearance,
immunogenicity and other PK/PD properties have yet to be
systematically studied. Nonetheless, signicant barriers to the
use of linear-peptide ligands have been surpassed using this class
of peptides, leading to candidates that have entered clinical
trials.11,122 The development of constrained peptides to target an
increasingly broad range of targets123–125 alongside their integra-
tion into proteolysis targeting chimeras126 ensures they can
condently be predicted to remain an important class of
compounds in chemical biology and drug discovery research.
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